{"gene":"FABP4","run_date":"2026-06-09T23:54:43","timeline":{"discoveries":[{"year":2021,"finding":"Hormonal FABP4 forms a functional hormone complex with adenosine kinase (ADK) and nucleoside diphosphate kinase (NDPK), designated 'Fabkin', to regulate extracellular ATP and ADP levels and thereby modulate beta-cell function; antibody-mediated targeting of this complex improved metabolic outcomes and preserved beta-cell integrity in mouse models of both type 1 and type 2 diabetes.","method":"Complex identification, in vivo mouse models (T1D and T2D), antibody-mediated targeting, measurement of extracellular ATP/ADP levels","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — complex reconstitution with functional readout, multiple disease models, antibody intervention, published in Nature","pmids":["34880500"],"is_preprint":false},{"year":2013,"finding":"FABP4 triggers ubiquitination and subsequent proteasomal degradation of PPARγ in adipocytes and macrophages, thereby downregulating adipogenesis; FABP4-null preadipocytes exhibit markedly enhanced adipogenesis that is reversed by FABP4 complementation.","method":"Ubiquitination assay, proteasome inhibition, FABP4-null mouse preadipocytes and macrophages, complementation rescue experiment","journal":"Diabetes","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal genetic rescue, ubiquitination assay, and multiple cell-type validation in one study","pmids":["24319114"],"is_preprint":false},{"year":2017,"finding":"FABP4 (A-FABP) promotes adaptive thermogenesis by inducing type-II iodothyronine deiodinase (DIO2) expression in brown adipocytes via inhibition of liver X receptor α (LXRα), leading to conversion of inactive T4 to active T3; A-FABP knockout mice have reduced thermogenesis reversible by recombinant A-FABP infusion.","method":"A-FABP knockout mice, cold stress and high-fat diet challenges, recombinant protein infusion rescue, gene expression analysis, LXRα inhibition assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — KO with specific phenotype, recombinant protein rescue, mechanistic pathway (LXRα inhibition → DIO2 induction) validated in multiple conditions","pmids":["28128199"],"is_preprint":false},{"year":2017,"finding":"FABP4 secretion from adipocytes occurs via an unconventional pathway involving enclosure within endosomes and secretory lysosomes, independent of the ER-Golgi pathway, GRASP proteins, autophagy, and multivesicular bodies; chloroquine treatment inhibits plasma FABP4 elevation in mice.","method":"Subcellular fractionation, membrane-bounded compartment tracing, pharmacological inhibition (chloroquine) in mice, exclusion of alternative secretory routes","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods to define secretory pathway, in vivo validation with chloroquine, published in a top cell biology journal","pmids":["29212659"],"is_preprint":false},{"year":2023,"finding":"Endothelial cells are the major source of baseline circulating (hormonal) FABP4, contributing ~87% of basal plasma FABP4; adipocytes are the main source of the lipolysis-stimulated rise in plasma FABP4 (~62% of induction); myeloid cells do not contribute detectably to circulating FABP4. Endothelial-derived FABP4 is required for the insulin secretion response to lipolysis.","method":"Cell-type-specific Fabp4 knockout mice (adipocyte, endothelial, myeloid, total), plasma FABP4 measurement, lipolysis stimulation, insulin secretion assay","journal":"JCI insight","confidence":"High","confidence_rationale":"Tier 2 / Strong — four cell-type-specific KO lines with rigorous in vivo quantification of plasma FABP4 and functional insulin secretion readout","pmids":["37279064"],"is_preprint":false},{"year":2024,"finding":"PAK4 directly phosphorylates FABP4 at T126 and HSL at S565, impairing the FABP4–HSL interaction and inhibiting lipolysis; adipose-specific PAK4 overexpression attenuates lipolysis and exacerbates obesity, whereas PAK4 knockout or inhibition enhances lipolysis and ameliorates diet-induced obesity and insulin resistance. PKA targets PAK4 for degradation, placing PAK4 as a counter-regulatory node in the cAMP-PKA lipolysis pathway.","method":"In vitro kinase assay with phosphosite identification, adipose-specific PAK4 overexpression and KO mice, co-IP of FABP4–HSL, high-fat diet metabolic phenotyping, PAK4 inhibitor treatment","journal":"Nature metabolism","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct kinase assay with mutagenesis-level phosphosite identification, reciprocal Co-IP, multiple in vivo genetic models","pmids":["38216738"],"is_preprint":false},{"year":2017,"finding":"Ablation of FABP4/aP2 in macrophages upregulates UCP2, reduces mitochondrial protein oxidation and the mitochondrial unfolded-protein response, and attenuates NLRP3 inflammasome activation and IL-1β secretion; these effects are partially reversed by UCP2 silencing in FABP4-null macrophages, establishing a FABP4→UCP2→redox→NLRP3 pathway.","method":"FABP4-null macrophages, UCP2 siRNA rescue, ROS/protein oxidation assays, NLRP3 inflammasome activation (caspase-1 cleavage, IL-1β secretion), chemical FABP4 inhibitor","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO with genetic rescue (siRNA), multiple orthogonal mechanistic readouts, chemical inhibitor confirmation","pmids":["27795298"],"is_preprint":false},{"year":2018,"finding":"Macrophage-derived FABP4 is required for CXCL1 production by alveolar macrophages and subsequent neutrophil recruitment in Pseudomonas aeruginosa pneumonia; bone marrow chimera experiments confirmed macrophages as the protective FABP4 source, and recombinant CXCL1 delivery rescued FABP4-null mice from increased mortality.","method":"FABP4-knockout mice, bone marrow chimera reconstitution, intratracheal P. aeruginosa challenge, recombinant CXCL1 rescue, CXCL1 ELISA from alveolar macrophages","journal":"FASEB journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal chimera experiment, in vivo rescue with recombinant protein, cell-type-specific attribution of CXCL1 production","pmids":["30462529"],"is_preprint":false},{"year":2022,"finding":"SIRT5 physically interacts with FABP4 (Co-IP) and promotes FABP4 deacetylation, reducing FABP4 expression and thereby promoting non-small cell lung cancer progression; silencing SIRT5 increases FABP4 acetylation and expression, reducing cancer cell malignancy.","method":"Co-immunoprecipitation, western blot for acetylation, shRNA knockdown of SIRT5 and FABP4 in NSCLC cells, in vivo xenograft","journal":"Neoplasma","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — Co-IP interaction and functional rescue, single lab, limited mechanistic depth on deacetylase specificity","pmids":["35603953"],"is_preprint":false},{"year":2018,"finding":"FABP4 interacts with cytokeratin 1 (CK1) on the endothelial cell surface (demonstrated by surface plasmon resonance); CK1-mediated FABP4 uptake regulates endothelial oxidative stress (NRF2) and inflammation (NF-κB/p65) responses, and CK1 knockdown blocks eFABP4 pro-inflammatory and pro-oxidative effects.","method":"Surface plasmon resonance (direct binding), siRNA knockdown of CK1 in HUVECs, western blotting for NRF2 and p65 nuclear translocation, palmitate co-treatment","journal":"Biochimica et biophysica acta. Molecular and cell biology of lipids","confidence":"Medium","confidence_rationale":"Tier 1–2 / Moderate — SPR direct binding with domain mapping, functional KD validation, single lab","pmids":["30521939"],"is_preprint":false},{"year":2021,"finding":"CD36 directly interacts with FABP4 to regulate fatty acid import, transport, and metabolism in breast cancer cells co-cultured with adipocytes; CD36 activates STAT3 signalling with a feedforward loop (STAT3 binds CD36 promoter), and combined CD36/FABP4 inhibition induces apoptosis.","method":"Co-culture experiments, genetic ablation of CD36, Co-IP of CD36–FABP4 interaction, ChIP/reporter for STAT3-CD36 promoter binding, apoptosis assays","journal":"NPJ breast cancer","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — direct Co-IP interaction, functional genetic ablation, single lab","pmids":["34561446"],"is_preprint":false},{"year":2021,"finding":"FABP4 in tumor-associated macrophages directly binds to ATP synthase β subunit (ATPB) and promotes its ubiquitination, leading to decreased intracellular ATP and deactivation of the NF-κB/RelA–IL-1α pathway, reprogramming macrophages to an anti-inflammatory phenotype that promotes neuroblastoma progression.","method":"Co-IP of FABP4–ATPB, ubiquitination assay, ATP measurement, NF-κB pathway analysis, IL-1α blocking antibody rescue, in vitro and in vivo tumor progression assays","journal":"Clinical and translational medicine","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — Co-IP and ubiquitination assay with functional rescue, single lab","pmids":["33931964"],"is_preprint":false},{"year":2021,"finding":"FABP4 activates the JAK2/STAT2 signaling pathway in homocysteine-induced macrophage inflammation via Rap1a-mediated Tyr416 phosphorylation and membrane translocation of c-Src; SOCS1 provides negative feedback inhibition of this pathway and reduces Rap1a expression.","method":"Western blot for JAK2/STAT2 and c-Src phosphorylation, Rap1a manipulation, pharmacological inhibition in ApoE-/- mice, pathway inhibitor studies","journal":"Laboratory investigation","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — defined signaling pathway with multiple nodes validated, single lab, in vivo and in vitro","pmids":["34725437"],"is_preprint":false},{"year":2024,"finding":"FABP4 activates the AMPK/JAK/STAT axis in a novel FABP4+C1q+ macrophage subtype, promoting fatty acid synthesis, anti-apoptosis, and phagocytic ability; FABP4 and C1q synergistically regulate proinflammatory cytokine expression in these macrophages.","method":"Single-cell RNA sequencing, multiplex fluorescent immunohistochemistry, mechanistic pathway (AMPK/JAK/STAT) analysis, functional phagocytosis/apoptosis assays","journal":"Cell death & disease","confidence":"Low","confidence_rationale":"Tier 3 / Weak — scRNA-seq identifies subtype, mechanistic pathway stated from 'further mechanistic studies' with limited biochemical detail in abstract","pmids":["39353883"],"is_preprint":false},{"year":2023,"finding":"FABP4 in liver sinusoidal endothelial cells (LSECs) promotes CXCL10 expression via NF-κB/p65 signaling, driving CXCR3+ macrophage recruitment and M1 macrophage polarization during NAFLD progression; FABP4 inhibition reduces CXCL10 and M1 polarization.","method":"FABP4 inhibition in HFD mice, flow cytometry for macrophage subtypes, co-culture of TMNK-1 cells with macrophages, NF-κB inhibitor, recombinant CXCL10 treatment","journal":"Biochimica et biophysica acta. Molecular basis of disease","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — pathway (NF-κB→CXCL10) validated with inhibitor and recombinant protein, in vivo and in vitro, single lab","pmids":["37487374"],"is_preprint":false},{"year":2019,"finding":"FABP4 supports fatty acid-induced PPARγ activation in IL-4-polarized macrophages, leading to upregulation of lipoprotein lipase (LPL), VLDL-induced triglyceride accumulation (foam cell formation), and CCL2/IL-1β inflammatory mediator expression; FABP4 inhibition (chemical or siRNA) reduces all these effects.","method":"FABP4 siRNA knockdown, chemical inhibitors (BMS309403, HTS01037), PPARγ luciferase reporter assay, lipid accumulation assay in primary human macrophages","journal":"Atherosclerosis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — PPARγ reporter assay plus siRNA and chemical inhibitor in primary human macrophages, single lab","pmids":["25897794"],"is_preprint":false},{"year":2019,"finding":"Exogenous FABP4 activates p38 MAPK, which mediates both HSL (Ser-660) phosphorylation-dependent lipolysis and NF-κB-mediated inflammation in adipocytes; these effects are blocked by the p38 inhibitor SB203580 and FABP4 inhibitor I-9 in vitro and in vivo.","method":"Recombinant FABP4 treatment of 3T3-L1 cells and C57BL/6J mice, western blot for p38, HSL-pSer660, NF-κB, p38 and FABP4 inhibitor intervention","journal":"Endocrine","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — signaling pathway validated with specific inhibitors in vitro and in vivo, single lab","pmids":["31845180"],"is_preprint":false},{"year":2022,"finding":"Microglial FABP4 deficiency prevents high-fat diet-induced cognitive decline in mice, associated with reduced hippocampal neuroinflammation (inflammatory cytokines and microgliosis) and increased microglial UCP2 expression, defining a microglial FABP4–UCP2 axis in diet-induced neuroinflammation.","method":"Microglial-specific FABP4 knockout (AKO) mice, HFD challenge, behavioral testing (T-maze, Barnes maze), hippocampal cytokine panel, UCP2 RT-PCR, IHC for microgliosis","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-type-specific KO with defined behavioral and molecular phenotype, multiple orthogonal readouts, single lab","pmids":["35457171"],"is_preprint":false},{"year":2018,"finding":"FABP4 expression in eosinophils is induced by TNF-α, IL-4, and IL-13; FABP4-deficient eosinophils show decreased spreading, adhesion (reduced β2-integrin), migration, F-actin polymerization, calcium flux, and ERK1/2 phosphorylation in response to eotaxin-1; in vivo, FABP4-null mice exhibit attenuated eosinophilia and airway inflammation in a cockroach antigen model.","method":"FABP4-knockout mice, allergen challenge model, eosinophil adhesion and migration assays, calcium flux measurement, ERK1/2 western blot, F-actin polymerization assay","journal":"American journal of physiology. Lung cellular and molecular physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal in vitro assays plus in vivo KO model, single lab","pmids":["29696987"],"is_preprint":false},{"year":2024,"finding":"FABP4 directly activates NF-κB signaling in chondrocytes (validated in ATDC5 cells and FABP4-KO vs WT mice), leading to upregulation of catabolic markers; dual FABP4 and NF-κB inhibition alleviates OA in high-fat diet mice, whereas FABP4 had no significant effect on JNK signaling in this context.","method":"FABP4-KO mice, NF-κB-specific inhibitor (QNZ) and siRNA, FABP4 inhibitor (BMS309403), ATDC5 chondrocyte culture with recombinant FABP4, HFD OA model","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — genetic KO, specific inhibitors and siRNA, in vitro direct stimulation, single lab","pmids":["38095503"],"is_preprint":false},{"year":2024,"finding":"FABP4 inhibition (BMS309403) suppresses osteoclast differentiation by modulating calcium signaling and inhibiting the Ca2+-Calcineurin-NFATc1 pathway, without affecting osteoblast differentiation, and increases bone mineral density in ovariectomized mice.","method":"Osteoclast/osteoblast differentiation assays, Ca2+ signaling and NFATc1 pathway analysis, ovariectomized mouse model with BMS309403 treatment, bone mineral density measurement","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — defined pathway (Ca2+-Calcineurin-NFATc1) with pharmacological inhibition and in vivo disease model, single lab","pmids":["40360512"],"is_preprint":false},{"year":2024,"finding":"FABP4 activates the FABP4/CEBPα pathway in macrophages in response to unsaturated fatty acids (particularly linoleic acid), leading to triglyceride synthesis and lipid droplet formation; FABP4 also enhances lipolysis and FA utilization by breast cancer cells, promoting metastasis in vitro and in vivo; FABP4 deficiency in macrophages significantly reduces linoleic acid-induced lipid metabolism.","method":"Murine macrophage lipid droplet formation assays, FABP4-deficient macrophages, CEBPα pathway analysis, co-culture with breast cancer cell lines, migration assays, in vivo metastasis model","journal":"eLife","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — genetic KO with multiple orthogonal assays (lipid metabolism, signaling, migration, in vivo), single lab","pmids":["39513934"],"is_preprint":false},{"year":2021,"finding":"FABP4 in macrophages activates the NLRP3/IL-1β axis by facilitating transfer of saturated fatty acids to induce caspase-1/GSDMD-dependent pyroptosis, which then promotes EMT signaling in pancreatic cancer cells to drive metastasis.","method":"In vivo and in vitro experiments with FABP4-overexpressing macrophages, caspase-1/GSDMD pathway analysis, NLRP3 inhibition, co-culture of macrophages with PC cells, EMT marker assessment","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — defined pathway with multiple nodes validated in vitro and in vivo, single lab","pmids":["37741433"],"is_preprint":false},{"year":2024,"finding":"FABP4 facilitates EMT in glioblastoma cells by upregulating CD36 expression, which promotes EMT via non-canonical TGFβ pathways; FABP4 overexpression increases filopodia formation and invasion, and loss-of-function reduces these effects in vitro and in an intracranial model.","method":"Gain- and loss-of-function experiments, DEG and GSEA analysis, CD36 expression assays, non-canonical TGFβ pathway western blot, intracranial glioma mouse model","journal":"Neoplasia","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — mechanistic pathway through CD36/TGFβ with in vitro and in vivo validation, single lab","pmids":["39243502"],"is_preprint":false},{"year":2019,"finding":"Nitro-fatty acids (NO2-FA) bind directly to FABP4 (demonstrated in vitro and in silico), and FABP4 facilitates NO2-FA-induced PPARγ, Keap1/Nrf2, and HSF1 signaling in monocytes; FABP4 inhibition attenuates these downstream signaling actions, establishing a FABP4-PPARγ positive amplification loop for NO2-FA signaling.","method":"In vitro fatty acid binding assay, molecular docking (in silico), FABP4 inhibitor treatment, PPARγ reporter gene assays in primary human monocytes/macrophages","journal":"Redox biology","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — direct binding demonstrated by in vitro and in silico approaches, functional inhibitor validation, single lab","pmids":["31926616"],"is_preprint":false},{"year":2024,"finding":"FABP4 promotes survival and alarming function of islet-resident memory T cells (TRM) by promoting fatty acid utilization and CXCL10 secretion; genetic deletion of FABP4 in NOD mice reduced cytotoxic T cell recruitment, delayed T1D incidence, and suppressed CXCL10 production.","method":"NOD mouse FABP4 genetic deletion, CD69 neutralizing antibody depletion of TRM cells, flow cytometry for T cell populations, CXCL10 measurement, diabetes incidence tracking","journal":"Advanced science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO with disease incidence readout and mechanistic CXCL10 link, parallel TRM depletion producing similar phenotype, single lab","pmids":["38884133"],"is_preprint":false},{"year":2023,"finding":"FABP4 controls fat mass homeostasis (adipocyte size and number) through a negative feedback loop: fatty acid-mediated FAT/CD36-PPARγ signaling induces FABP4 expression, and accumulated intracellular FABP4 in turn inhibits CD36 signaling in both adipocytes and progenitors.","method":"Real-time proliferation/differentiation/lipolysis assays in 3T3-L1, 3T3-MBX, and human adipose stem cells; co-culture; FABP4 uptake and CD36 signaling measurements","journal":"International journal of molecular sciences","confidence":"Low","confidence_rationale":"Tier 3 / Weak — cell-based assays with mechanistic proposal, single lab, limited biochemical depth in abstract","pmids":["36674544"],"is_preprint":false},{"year":2021,"finding":"FABP4 expressed in Paneth cells is regulated by gut Lactobacillus via TRAF2/TRAF6 ubiquitination-mediated NF-κB signaling; germ-free mice have reduced intestinal FABP4, restored by fecal transplantation or specific Lactobacillus colonization.","method":"Germ-free mice, fecal transplantation, Lactobacillus colonization, TRAF2/TRAF6 ubiquitination and NF-κB pathway analysis, Paneth cell-specific FABP4 expression assessment","journal":"Scientific reports","confidence":"Low","confidence_rationale":"Tier 3 / Weak — pathway identified but mechanistic link between TRAF2/6 NF-κB and FABP4 induction in Paneth cells has limited biochemical detail in abstract, single lab","pmids":["26687459"],"is_preprint":false},{"year":2024,"finding":"Fatty acid binding to FABP4 occurs in two distinct states ('intermediately' and 'strongly' bound) as revealed by CW EPR spectroscopy using spin-labeled stearic acid; binding proportions are strongly temperature- and concentration-dependent with the more dynamic 'intermediately bound' state dominating at body temperature.","method":"Microscale thermophoresis (MST), continuous-wave electron paramagnetic resonance (CW EPR) spectroscopy with spin-probe ligands, dynamic light scattering, bioinformatic analysis","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — biophysical characterization of ligand binding mechanism with two orthogonal methods, single lab, no mutagenesis or cellular functional validation","pmids":["38777142"],"is_preprint":false},{"year":2023,"finding":"Kindlin-2 stabilizes fatty acid synthase (FAS) and promotes PPARγ activation and downstream FABP4 expression in adipocytes; increased FABP4 inhibits insulin expression and decreases bone mass; Kindlin-2 deletion reduces FABP4 and increases bone mass, reversible by PPARγ activation (rosiglitazone), establishing a Kindlin-2/FAS/PPARγ/FABP4/insulin axis.","method":"Adipocyte-specific Kindlin-2 KO mice, AAV-targeted knockdown, FAS inhibitor (C75), rosiglitazone rescue, FAS protein stability assay, PPARγ activation assay, bone density measurement","journal":"Acta pharmaceutica Sinica. B","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO with pharmacological rescue defining epistatic pathway, multiple in vivo and in vitro validations, single lab","pmids":["37969743"],"is_preprint":false},{"year":2021,"finding":"PXR mediates FABP4 expression in response to valproate in HepG2 cells; PXR knockdown reduces both FABP4 induction and lipid accumulation, while PXR overexpression enhances both; exogenous FABP4 overexpression independently increases triglyceride levels.","method":"PXR siRNA knockdown, PXR overexpression, FABP4 overexpression, triglyceride measurement, lipid accumulation assay in HepG2 cells","journal":"Toxicology letters","confidence":"Low","confidence_rationale":"Tier 3 / Weak — cell-based assays with genetic manipulations, single lab, indirect pathway inference","pmids":["33901630"],"is_preprint":false},{"year":2022,"finding":"mTORC1 activity (controlled by TSC1 deletion or Rheb1 disruption in myeloid cells) regulates FABP4 expression in macrophages; mTORC1 activation increases FABP4 secretion from M1-polarized macrophages, promoting synovitis, angiogenesis, and cartilage degradation in RA; anagliptin (DPP4 inhibitor) and BMS309403 (FABP4 inhibitor) reduce FABP4 in synovial macrophages and alleviate RA.","method":"Myeloid-specific TSC1-deletion and Rheb1-disruption mice, BMS309403 and anagliptin treatment, in vivo RA mouse model, synovitis/angiogenesis/cartilage assays","journal":"Bone research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — myeloid-specific genetic models defining mTORC1→FABP4 axis, pharmacological validation, in vivo disease readouts, single lab","pmids":["35729106"],"is_preprint":false},{"year":2024,"finding":"FABP4 induces fibrosis, lipid accumulation, and altered glucose metabolism in epicardial stroma and atrial fibroblasts, and modifies lipid content and calcium dynamics in atrial cardiomyocytes, without affecting INa; these effects were demonstrated by direct FABP4 protein treatment of primary cell cultures.","method":"Primary epicardial/subcutaneous stroma and atrial fibroblast cultures, iPSC-derived and adult mouse atrial cardiomyocytes, FABP4 (100 ng/mL) treatment, proteomics, Raman microspectroscopy, calcium imaging, patch clamp","journal":"Circulation. Arrhythmia and electrophysiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple primary cell types, orthogonal methods including electrophysiology and proteomics, direct protein treatment, single lab","pmids":["39212041"],"is_preprint":false}],"current_model":"FABP4 is an intracellular lipid chaperone and secreted hormone (released from adipocytes during lipolysis and constitutively from endothelial cells) that forms a functional hormone complex (Fabkin) with ADK and NDPK to regulate extracellular nucleotide levels and beta-cell function; intracellularly, it promotes proteasomal degradation of PPARγ to suppress adipogenesis, controls macrophage redox signaling and NLRP3 inflammasome activation via UCP2, is phosphorylated by PAK4 at T126 to impair its interaction with HSL and inhibit lipolysis, and is deacetylated by SIRT5; extracellularly, it signals through cytokeratin 1 on endothelial cells to activate NF-κB and oxidative stress pathways, and in brown adipocytes promotes thermogenesis by inhibiting LXRα to induce DIO2-mediated T4-to-T3 conversion."},"narrative":{"mechanistic_narrative":"FABP4 is a fatty acid-binding protein that functions both as an intracellular lipid chaperone and as a secreted hormone coordinating lipid metabolism, inflammation, and systemic glucose homeostasis [PMID:34880500, PMID:37279064]. As a circulating hormone, FABP4 is released from adipocytes upon lipolytic stimulation and constitutively from endothelial cells, which supply the majority of basal plasma FABP4 and are required for the lipolysis-driven insulin secretion response [PMID:37279064]; its secretion proceeds through an unconventional ER-Golgi-independent route involving endosomes and secretory lysosomes [PMID:29212659]. Once extracellular, FABP4 assembles with adenosine kinase and nucleoside diphosphate kinase into the 'Fabkin' complex that regulates extracellular ATP/ADP levels and modulates beta-cell function, and antibody targeting of this complex improves metabolic outcomes in diabetes models [PMID:34880500]; it also engages cytokeratin 1 on the endothelial surface to drive NRF2 oxidative-stress and NF-κB inflammatory signaling [PMID:30521939]. Intracellularly, FABP4 binds fatty acids in distinct dynamic states [PMID:38777142] and shapes nuclear-receptor signaling: it triggers ubiquitin-proteasomal degradation of PPARγ to restrain adipogenesis [PMID:24319114], yet supports fatty acid-induced PPARγ activation and lipid signaling in polarized macrophages [PMID:25897794, PMID:31926616]. Its lipolytic role is gated by PAK4, which phosphorylates FABP4 at T126 to impair the FABP4–HSL interaction and suppress lipolysis [PMID:38216738]. In brown adipocytes FABP4 promotes adaptive thermogenesis by inhibiting LXRα to induce DIO2-mediated T4-to-T3 conversion [PMID:28128199], and in macrophages it controls a UCP2-dependent redox circuit that governs NLRP3 inflammasome activation and IL-1β output [PMID:27795298]. Across diverse immune and stromal contexts FABP4 acts as a pro-inflammatory node, driving NF-κB-dependent chemokine production and macrophage recruitment in tissue and tumor microenvironments [PMID:37487374, PMID:33931964, PMID:39513934].","teleology":[{"year":2013,"claim":"Established that beyond lipid binding FABP4 actively regulates the master adipogenic transcription factor PPARγ, explaining how it restrains fat-cell formation.","evidence":"Ubiquitination and proteasome-inhibition assays with FABP4-null preadipocyte/macrophage complementation rescue","pmids":["24319114"],"confidence":"High","gaps":["Does not define the E3 ligase or direct biochemical mechanism of PPARγ ubiquitination","Reconciliation with FABP4 supporting PPARγ activation in macrophages unresolved"]},{"year":2017,"claim":"Showed FABP4 drives adaptive thermogenesis through an LXRα→DIO2 axis, linking the chaperone to thyroid hormone activation in brown fat.","evidence":"A-FABP knockout mice with cold/HFD challenge and recombinant protein rescue, LXRα inhibition assays","pmids":["28128199"],"confidence":"High","gaps":["Mechanism by which FABP4 inhibits LXRα not defined","Direct vs indirect effect on DIO2 transcription unclear"]},{"year":2017,"claim":"Defined the unconventional secretory route for FABP4, resolving how a cytosolic protein reaches the circulation.","evidence":"Subcellular fractionation, exclusion of ER-Golgi/GRASP/autophagy/MVB routes, chloroquine inhibition in vivo","pmids":["29212659"],"confidence":"High","gaps":["Molecular machinery sorting FABP4 into endosomes/secretory lysosomes unknown","Signal triggering release not identified"]},{"year":2017,"claim":"Connected FABP4 to a UCP2-dependent redox circuit controlling NLRP3 inflammasome activity, a mechanism for its pro-inflammatory action in macrophages.","evidence":"FABP4-null macrophages with UCP2 siRNA rescue, ROS/protein-oxidation and caspase-1/IL-1β readouts, chemical inhibitor","pmids":["27795298"],"confidence":"High","gaps":["How FABP4 represses UCP2 mechanistically not established","Link between lipid binding and mitochondrial redox not biochemically resolved"]},{"year":2021,"claim":"Identified FABP4 as a secreted hormone forming the Fabkin complex that regulates extracellular nucleotides and beta-cell function, a paradigm-shifting extracellular role.","evidence":"Complex identification, T1D/T2D mouse models, antibody-mediated targeting, extracellular ATP/ADP measurement","pmids":["34880500"],"confidence":"High","gaps":["Structural basis of the Fabkin assembly not resolved","Receptor/sensing mechanism on beta-cells unclear"]},{"year":2018,"claim":"Demonstrated a direct extracellular receptor for FABP4 (cytokeratin 1) on endothelial cells, defining how circulating FABP4 transmits oxidative/inflammatory signals.","evidence":"Surface plasmon resonance binding, CK1 siRNA knockdown in HUVECs, NRF2/p65 readouts","pmids":["30521939"],"confidence":"Medium","gaps":["Single lab, no in vivo CK1 genetic validation","Downstream signal transduction from CK1 not defined"]},{"year":2023,"claim":"Quantified the cellular origins of circulating FABP4, showing endothelium supplies basal hormone and adipocytes the lipolytic surge, refining the source of the metabolic hormone.","evidence":"Four cell-type-specific Fabp4 knockout lines, plasma FABP4 quantification, lipolysis and insulin secretion assays","pmids":["37279064"],"confidence":"High","gaps":["Mechanism of constitutive endothelial secretion not defined","How endothelial FABP4 couples to islet insulin secretion unresolved"]},{"year":2024,"claim":"Placed FABP4 under kinase control by PAK4, identifying a phosphosite that gates the FABP4–HSL interaction and lipolysis within the cAMP-PKA axis.","evidence":"In vitro kinase assay with phosphosite mapping (T126), adipose-specific PAK4 OE/KO mice, FABP4–HSL co-IP","pmids":["38216738"],"confidence":"High","gaps":["Structural effect of T126 phosphorylation on FABP4 not resolved","Whether phospho-FABP4 alters lipid binding unknown"]},{"year":2024,"claim":"Characterized the biophysics of FABP4 ligand binding, revealing temperature-dependent intermediate and strongly bound fatty acid states.","evidence":"Microscale thermophoresis and CW EPR with spin-labeled stearic acid","pmids":["38777142"],"confidence":"Medium","gaps":["No mutagenesis linking binding states to function","Cellular relevance of the two states untested"]},{"year":2024,"claim":"Extended FABP4's pro-inflammatory function across tissues, showing NF-κB-driven chemokine programs in endothelium, macrophages, T cells, and stroma promote recruitment and disease in metabolic, autoimmune, and tumor settings.","evidence":"Cell-type-specific KO and inhibitor studies across NAFLD, NOD diabetes, cancer co-culture and metastasis models with CXCL10/CXCL1/IL-1 readouts","pmids":["37487374","38884133","30462529","37741433","39513934"],"confidence":"Medium","gaps":["Whether these effects depend on intracellular lipid chaperoning or extracellular signaling not always distinguished","Most contexts validated in single labs"]},{"year":null,"claim":"How a single fatty acid-binding protein reconciles opposing roles (PPARγ degradation vs activation; intracellular chaperone vs extracellular hormone) and the structural/receptor basis of its extracellular signaling remain open.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unifying structural model linking ligand state, phosphorylation, and partner choice","Extracellular receptor repertoire beyond CK1 unresolved","Mechanism switching FABP4 between pro- and anti-adipogenic outputs unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[28,24]},{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[0,9]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[1,2,5]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[3,5]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,4]},{"term_id":"GO:0005764","term_label":"lysosome","supporting_discovery_ids":[3]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[3]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[1,2,26]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[6,14,7]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,9,5]},{"term_id":"R-HSA-9609507","term_label":"Protein localization","supporting_discovery_ids":[3]}],"complexes":["Fabkin (FABP4-ADK-NDPK)"],"partners":["ADK","NDPK","HSL","PAK4","PPARG","KRT1","CD36","SIRT5"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P15090","full_name":"Fatty acid-binding protein, adipocyte","aliases":["Adipocyte lipid-binding protein","ALBP","Adipocyte-type fatty acid-binding protein","A-FABP","AFABP","Fatty acid-binding protein 4"],"length_aa":132,"mass_kda":14.7,"function":"Lipid transport protein in adipocytes. Binds both long chain fatty acids and retinoic acid. Delivers long-chain fatty acids and retinoic acid to their cognate receptors in the nucleus","subcellular_location":"Cytoplasm; Nucleus","url":"https://www.uniprot.org/uniprotkb/P15090/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/FABP4","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/FABP4","total_profiled":1310},"omim":[{"mim_id":"620847","title":"BONE MORPHOGENETIC PROTEIN 8A; BMP8A","url":"https://www.omim.org/entry/620847"},{"mim_id":"619246","title":"SPEXIN HORMONE; SPX","url":"https://www.omim.org/entry/619246"},{"mim_id":"618923","title":"FATTY ACID-BINDING PROTEIN 12; FABP12","url":"https://www.omim.org/entry/618923"},{"mim_id":"612991","title":"ASXL TRANSCRIPTIONAL REGULATOR 2; ASXL2","url":"https://www.omim.org/entry/612991"},{"mim_id":"612990","title":"ASXL TRANSCRIPTIONAL REGULATOR 1; ASXL1","url":"https://www.omim.org/entry/612990"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"},{"location":"Cytosol","reliability":"Approved"}],"tissue_specificity":"Group enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"adipose tissue","ntpm":3555.6},{"tissue":"breast","ntpm":2416.5}],"url":"https://www.proteinatlas.org/search/FABP4"},"hgnc":{"alias_symbol":["A-FABP","aP2"],"prev_symbol":[]},"alphafold":{"accession":"P15090","domains":[{"cath_id":"2.40.128.20","chopping":"2-130","consensus_level":"high","plddt":96.0888,"start":2,"end":130}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P15090","model_url":"https://alphafold.ebi.ac.uk/files/AF-P15090-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P15090-F1-predicted_aligned_error_v6.png","plddt_mean":95.75},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=FABP4","jax_strain_url":"https://www.jax.org/strain/search?query=FABP4"},"sequence":{"accession":"P15090","fasta_url":"https://rest.uniprot.org/uniprotkb/P15090.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P15090/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P15090"}},"corpus_meta":[{"pmid":"25674026","id":"PMC_25674026","title":"Fatty Acid-Binding Protein 4 (FABP4): Pathophysiological Insights and Potent Clinical Biomarker of Metabolic and Cardiovascular Diseases.","date":"2015","source":"Clinical Medicine Insights. Cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/25674026","citation_count":374,"is_preprint":false},{"pmid":"24319114","id":"PMC_24319114","title":"FABP4 attenuates PPARγ and adipogenesis and is inversely correlated with PPARγ in adipose tissues.","date":"2013","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/24319114","citation_count":272,"is_preprint":false},{"pmid":"32054768","id":"PMC_32054768","title":"Adipocyte-Induced FABP4 Expression in Ovarian Cancer Cells Promotes Metastasis and Mediates Carboplatin Resistance.","date":"2020","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/32054768","citation_count":234,"is_preprint":false},{"pmid":"34030117","id":"PMC_34030117","title":"Tumor resistance to ferroptosis driven by Stearoyl-CoA Desaturase-1 (SCD1) in cancer cells and Fatty Acid Biding Protein-4 (FABP4) in tumor microenvironment promote tumor recurrence.","date":"2021","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/34030117","citation_count":231,"is_preprint":false},{"pmid":"30050129","id":"PMC_30050129","title":"FABP4 as a key determinant of metastatic potential of ovarian cancer.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/30050129","citation_count":181,"is_preprint":false},{"pmid":"30705117","id":"PMC_30705117","title":"Adipokine FABP4 integrates energy stores and counterregulatory metabolic responses.","date":"2019","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/30705117","citation_count":158,"is_preprint":false},{"pmid":"34561446","id":"PMC_34561446","title":"Interaction between CD36 and FABP4 modulates adipocyte-induced fatty acid import and metabolism in breast cancer.","date":"2021","source":"NPJ breast cancer","url":"https://pubmed.ncbi.nlm.nih.gov/34561446","citation_count":130,"is_preprint":false},{"pmid":"35729106","id":"PMC_35729106","title":"FABP4 secreted by M1-polarized macrophages promotes synovitis and angiogenesis to exacerbate rheumatoid arthritis.","date":"2022","source":"Bone research","url":"https://pubmed.ncbi.nlm.nih.gov/35729106","citation_count":97,"is_preprint":false},{"pmid":"33088219","id":"PMC_33088219","title":"FABP4 promotes invasion and metastasis of colon cancer by regulating fatty acid transport.","date":"2020","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/33088219","citation_count":92,"is_preprint":false},{"pmid":"28738306","id":"PMC_28738306","title":"Adipocyte fatty acid binding protein 4 (FABP4) inhibitors. A comprehensive systematic review.","date":"2017","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28738306","citation_count":81,"is_preprint":false},{"pmid":"28128199","id":"PMC_28128199","title":"A-FABP mediates adaptive thermogenesis by promoting intracellular activation of thyroid hormones in brown adipocytes.","date":"2017","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/28128199","citation_count":81,"is_preprint":false},{"pmid":"34880500","id":"PMC_34880500","title":"A hormone complex of FABP4 and nucleoside kinases regulates islet function.","date":"2021","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/34880500","citation_count":80,"is_preprint":false},{"pmid":"27795298","id":"PMC_27795298","title":"FABP4/aP2 Regulates Macrophage Redox Signaling and Inflammasome Activation via Control of UCP2.","date":"2017","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/27795298","citation_count":79,"is_preprint":false},{"pmid":"29212659","id":"PMC_29212659","title":"Unconventional secretion of FABP4 by endosomes and secretory lysosomes.","date":"2017","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/29212659","citation_count":78,"is_preprint":false},{"pmid":"34803493","id":"PMC_34803493","title":"Targeted Inhibition of LPL/FABP4/CPT1 fatty acid metabolic axis can effectively prevent the progression of nonalcoholic steatohepatitis to liver cancer.","date":"2021","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34803493","citation_count":71,"is_preprint":false},{"pmid":"23139800","id":"PMC_23139800","title":"FABP4 dynamics in obesity: discrepancies in adipose tissue and liver expression regarding circulating plasma levels.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23139800","citation_count":69,"is_preprint":false},{"pmid":"15110783","id":"PMC_15110783","title":"Atorvastatin reduces CD68, FABP4, and HBP expression in oxLDL-treated human macrophages.","date":"2004","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/15110783","citation_count":68,"is_preprint":false},{"pmid":"32359475","id":"PMC_32359475","title":"FABP4: A New Player in Obesity-Associated Breast Cancer.","date":"2020","source":"Trends in molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32359475","citation_count":67,"is_preprint":false},{"pmid":"27568980","id":"PMC_27568980","title":"Antiangiogenic and tumour inhibitory effects of downregulating tumour endothelial FABP4.","date":"2016","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/27568980","citation_count":65,"is_preprint":false},{"pmid":"37741433","id":"PMC_37741433","title":"FABP4 in macrophages facilitates obesity-associated pancreatic cancer progression via the NLRP3/IL-1β axis.","date":"2023","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/37741433","citation_count":57,"is_preprint":false},{"pmid":"31651326","id":"PMC_31651326","title":"High expression of FABP4 and FABP6 in patients with colorectal cancer.","date":"2019","source":"World journal of surgical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/31651326","citation_count":55,"is_preprint":false},{"pmid":"31845180","id":"PMC_31845180","title":"Exogenous FABP4 interferes with differentiation, promotes lipolysis and inflammation in adipocytes.","date":"2019","source":"Endocrine","url":"https://pubmed.ncbi.nlm.nih.gov/31845180","citation_count":52,"is_preprint":false},{"pmid":"31097687","id":"PMC_31097687","title":"FABP4 contributes to renal interstitial fibrosis via mediating inflammation and lipid metabolism.","date":"2019","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/31097687","citation_count":48,"is_preprint":false},{"pmid":"35899119","id":"PMC_35899119","title":"Therapeutic Implications of FABP4 in Cancer: An Emerging Target to Tackle Cancer.","date":"2022","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/35899119","citation_count":47,"is_preprint":false},{"pmid":"31926616","id":"PMC_31926616","title":"A FABP4-PPARγ signaling axis regulates human monocyte responses to electrophilic fatty acid nitroalkenes.","date":"2019","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/31926616","citation_count":47,"is_preprint":false},{"pmid":"25897794","id":"PMC_25897794","title":"FABP4 inhibition suppresses PPARγ activity and VLDL-induced foam cell formation in IL-4-polarized human macrophages.","date":"2015","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/25897794","citation_count":46,"is_preprint":false},{"pmid":"35849941","id":"PMC_35849941","title":"Adipocyte fatty acid binding protein 4 (FABP4) inhibitors. An update from 2017 to early 2022.","date":"2022","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/35849941","citation_count":44,"is_preprint":false},{"pmid":"33615754","id":"PMC_33615754","title":"High expression of FABP4 in colorectal cancer and its clinical significance.","date":"2021","source":"Journal of Zhejiang University. Science. B","url":"https://pubmed.ncbi.nlm.nih.gov/33615754","citation_count":40,"is_preprint":false},{"pmid":"36842611","id":"PMC_36842611","title":"Targeting FABP4 in elderly mice rejuvenates liver metabolism and ameliorates aging-associated metabolic disorders.","date":"2023","source":"Metabolism: clinical and experimental","url":"https://pubmed.ncbi.nlm.nih.gov/36842611","citation_count":39,"is_preprint":false},{"pmid":"34502295","id":"PMC_34502295","title":"A-FABP in Metabolic Diseases and the Therapeutic Implications: An Update.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34502295","citation_count":39,"is_preprint":false},{"pmid":"33931964","id":"PMC_33931964","title":"FABP4 deactivates NF-κB-IL1α pathway by ubiquitinating ATPB in tumor-associated macrophages and promotes neuroblastoma progression.","date":"2021","source":"Clinical and translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33931964","citation_count":38,"is_preprint":false},{"pmid":"34725437","id":"PMC_34725437","title":"FABP4 activates the JAK2/STAT2 pathway via Rap1a in the homocysteine-induced macrophage inflammatory response in ApoE-/- mice atherosclerosis.","date":"2021","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/34725437","citation_count":38,"is_preprint":false},{"pmid":"29696987","id":"PMC_29696987","title":"FABP4 regulates eosinophil recruitment and activation in allergic airway inflammation.","date":"2018","source":"American journal of physiology. Lung cellular and molecular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/29696987","citation_count":36,"is_preprint":false},{"pmid":"20024783","id":"PMC_20024783","title":"Associations of A-FABP and H-FABP markers with the content of intramuscular fat in Beijing-You chicken.","date":"2010","source":"Animal biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/20024783","citation_count":36,"is_preprint":false},{"pmid":"30462529","id":"PMC_30462529","title":"Macrophage FABP4 is required for neutrophil recruitment and bacterial clearance in Pseudomonas aeruginosa pneumonia.","date":"2018","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/30462529","citation_count":36,"is_preprint":false},{"pmid":"33597568","id":"PMC_33597568","title":"Elevated circulating FABP4 concentration predicts cardiovascular death in a general population: a 12-year prospective study.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/33597568","citation_count":35,"is_preprint":false},{"pmid":"36674544","id":"PMC_36674544","title":"FABP4 Controls Fat Mass Expandability (Adipocyte Size and Number) through Inhibition of CD36/SR-B2 Signalling.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36674544","citation_count":33,"is_preprint":false},{"pmid":"25280936","id":"PMC_25280936","title":"fabp4 is central to eight obesity associated genes: a functional gene network-based polymorphic study.","date":"2014","source":"Journal of theoretical biology","url":"https://pubmed.ncbi.nlm.nih.gov/25280936","citation_count":33,"is_preprint":false},{"pmid":"29393670","id":"PMC_29393670","title":"FABP4 as a biomarker for knee osteoarthritis.","date":"2018","source":"Biomarkers in medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29393670","citation_count":32,"is_preprint":false},{"pmid":"39306229","id":"PMC_39306229","title":"FABP4-mediated lipid metabolism promotes TNBC progression and breast cancer stem cell activity.","date":"2024","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/39306229","citation_count":31,"is_preprint":false},{"pmid":"38377465","id":"PMC_38377465","title":"Oleic acid-PPARγ-FABP4 loop fuels cholangiocarcinoma colonization in lymph node metastases microenvironment.","date":"2024","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/38377465","citation_count":31,"is_preprint":false},{"pmid":"37487374","id":"PMC_37487374","title":"FABP4 in LSECs promotes CXCL10-mediated macrophage recruitment and M1 polarization during NAFLD progression.","date":"2023","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/37487374","citation_count":31,"is_preprint":false},{"pmid":"24215402","id":"PMC_24215402","title":"Increased leptin and A-FABP levels in relapsing and progressive forms of MS.","date":"2013","source":"BMC neurology","url":"https://pubmed.ncbi.nlm.nih.gov/24215402","citation_count":31,"is_preprint":false},{"pmid":"30306857","id":"PMC_30306857","title":"Role of Fatty Acid Binding Protein 4 (FABP4) in Kidney Disease.","date":"2020","source":"Current medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30306857","citation_count":29,"is_preprint":false},{"pmid":"17057239","id":"PMC_17057239","title":"Unexpected high polymorphism at the FABP4 gene unveils a complex history for pig populations.","date":"2006","source":"Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17057239","citation_count":29,"is_preprint":false},{"pmid":"27936164","id":"PMC_27936164","title":"Transcriptome and Metabolome Analyses in Exogenous FABP4- and FABP5-Treated Adipose-Derived Stem Cells.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/27936164","citation_count":29,"is_preprint":false},{"pmid":"18535557","id":"PMC_18535557","title":"A-FABP--a biomarker associated with the metabolic syndrome and/or an indicator of weight change?","date":"2008","source":"Obesity (Silver Spring, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/18535557","citation_count":27,"is_preprint":false},{"pmid":"24390652","id":"PMC_24390652","title":"Circulating FABP4 is a marker of metabolic and cardiovascular risk in SLE patients.","date":"2014","source":"Lupus","url":"https://pubmed.ncbi.nlm.nih.gov/24390652","citation_count":27,"is_preprint":false},{"pmid":"37905351","id":"PMC_37905351","title":"Oridonin attenuates atherosclerosis by inhibiting foam macrophage formation and inflammation through FABP4/PPARγ signalling.","date":"2023","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37905351","citation_count":27,"is_preprint":false},{"pmid":"38216738","id":"PMC_38216738","title":"p21-activated kinase 4 counteracts PKA-dependent lipolysis by phosphorylating FABP4 and HSL.","date":"2024","source":"Nature metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/38216738","citation_count":26,"is_preprint":false},{"pmid":"26687459","id":"PMC_26687459","title":"Expression of FABP4, adipsin and adiponectin in Paneth cells is modulated by gut Lactobacillus.","date":"2015","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26687459","citation_count":26,"is_preprint":false},{"pmid":"38698167","id":"PMC_38698167","title":"The Effects of FABP4 on Cardiovascular Disease in the Aging Population.","date":"2024","source":"Current atherosclerosis reports","url":"https://pubmed.ncbi.nlm.nih.gov/38698167","citation_count":25,"is_preprint":false},{"pmid":"37272103","id":"PMC_37272103","title":"FABP4 Regulates Cell Proliferation, Stemness, Apoptosis, and Glycolysis in Colorectal Cancer via Modulating ROS/ERK/mTOR Pathway.","date":"2023","source":"Discovery medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37272103","citation_count":25,"is_preprint":false},{"pmid":"27236410","id":"PMC_27236410","title":"Altered CSNK1E, FABP4 and NEFH protein levels in the dorsolateral prefrontal cortex in schizophrenia.","date":"2016","source":"Schizophrenia research","url":"https://pubmed.ncbi.nlm.nih.gov/27236410","citation_count":24,"is_preprint":false},{"pmid":"31897106","id":"PMC_31897106","title":"Expression and correlation of Chemerin and FABP4 in peripheral blood of gestational diabetes mellitus patients.","date":"2019","source":"Experimental and therapeutic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31897106","citation_count":24,"is_preprint":false},{"pmid":"33071982","id":"PMC_33071982","title":"Independent and Distinct Associations of FABP4 and FABP5 With Metabolic Parameters in Type 2 Diabetes Mellitus.","date":"2020","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/33071982","citation_count":24,"is_preprint":false},{"pmid":"39513934","id":"PMC_39513934","title":"FABP4-mediated lipid accumulation and lipolysis in tumor-associated macrophages promote breast cancer metastasis.","date":"2024","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/39513934","citation_count":23,"is_preprint":false},{"pmid":"37279064","id":"PMC_37279064","title":"Endothelial-derived FABP4 constitutes the majority of basal circulating hormone and regulates lipolysis-driven insulin secretion.","date":"2023","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/37279064","citation_count":23,"is_preprint":false},{"pmid":"28847153","id":"PMC_28847153","title":"FABP4 and Cardiovascular Events in Peripheral Arterial Disease.","date":"2017","source":"Angiology","url":"https://pubmed.ncbi.nlm.nih.gov/28847153","citation_count":23,"is_preprint":false},{"pmid":"32861247","id":"PMC_32861247","title":"Circulating FABP4, nesfatin-1, and osteocalcin concentrations in women with gestational diabetes mellitus: a meta-analysis.","date":"2020","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/32861247","citation_count":22,"is_preprint":false},{"pmid":"33378030","id":"PMC_33378030","title":"FABP4 inhibitor attenuates inflammation and endoplasmic reticulum stress of islet in leptin receptor knockout rats.","date":"2020","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33378030","citation_count":22,"is_preprint":false},{"pmid":"39453486","id":"PMC_39453486","title":"Gut microbiota-derived acetic acids promoted sepsis-induced acute respiratory distress syndrome by delaying neutrophil apoptosis through FABP4.","date":"2024","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/39453486","citation_count":21,"is_preprint":false},{"pmid":"37969743","id":"PMC_37969743","title":"Targeting Kindlin-2 in adipocytes increases bone mass through inhibiting FAS/PPARγ/FABP4 signaling in mice.","date":"2023","source":"Acta pharmaceutica Sinica. B","url":"https://pubmed.ncbi.nlm.nih.gov/37969743","citation_count":21,"is_preprint":false},{"pmid":"37354697","id":"PMC_37354697","title":"Identification of Andrographolide as a novel FABP4 inhibitor for osteoarthritis treatment.","date":"2023","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37354697","citation_count":21,"is_preprint":false},{"pmid":"30015163","id":"PMC_30015163","title":"Variation in the FABP4 gene affects carcass and growth traits in sheep.","date":"2018","source":"Meat science","url":"https://pubmed.ncbi.nlm.nih.gov/30015163","citation_count":21,"is_preprint":false},{"pmid":"29850615","id":"PMC_29850615","title":"Intermittent High Glucose Exacerbates A-FABP Activation and Inflammatory Response through TLR4-JNK Signaling in THP-1 Cells.","date":"2018","source":"Journal of immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/29850615","citation_count":21,"is_preprint":false},{"pmid":"19844814","id":"PMC_19844814","title":"FABP4: a novel candidate gene for polycystic ovary syndrome.","date":"2009","source":"Endocrine","url":"https://pubmed.ncbi.nlm.nih.gov/19844814","citation_count":20,"is_preprint":false},{"pmid":"34244239","id":"PMC_34244239","title":"The Low-Expression Variant of FABP4 Is Associated With Cardiovascular Disease in Type 1 Diabetes.","date":"2021","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/34244239","citation_count":19,"is_preprint":false},{"pmid":"31927390","id":"PMC_31927390","title":"Relationships between visceral/subcutaneous adipose tissue FABP4 expression and coronary atherosclerosis in patients with metabolic syndrome.","date":"2019","source":"Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology","url":"https://pubmed.ncbi.nlm.nih.gov/31927390","citation_count":19,"is_preprint":false},{"pmid":"27856250","id":"PMC_27856250","title":"Ectopical expression of FABP4 gene can induce bovine muscle-derived stem cells adipogenesis.","date":"2016","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/27856250","citation_count":18,"is_preprint":false},{"pmid":"35457171","id":"PMC_35457171","title":"Microglial FABP4-UCP2 Axis Modulates Neuroinflammation and Cognitive Decline in Obese Mice.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35457171","citation_count":18,"is_preprint":false},{"pmid":"38884133","id":"PMC_38884133","title":"Islet-Resident Memory T Cells Orchestrate the Immunopathogenesis of Type 1 Diabetes through the FABP4-CXCL10 Axis.","date":"2024","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/38884133","citation_count":17,"is_preprint":false},{"pmid":"39353883","id":"PMC_39353883","title":"Novel FABP4+C1q+ macrophages enhance antitumor immunity and associated with response to neoadjuvant pembrolizumab and chemotherapy in NSCLC via AMPK/JAK/STAT axis.","date":"2024","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/39353883","citation_count":16,"is_preprint":false},{"pmid":"36609276","id":"PMC_36609276","title":"Fatty acid-binding protein-4 (FABP4) and matrix metalloproteinase-9 (MMP9) as predictive values for nonalcoholic steatohepatitis (NASH).","date":"2023","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/36609276","citation_count":16,"is_preprint":false},{"pmid":"30536325","id":"PMC_30536325","title":"FABP4 accelerates glioblastoma cell growth and metastasis through Wnt10b signalling.","date":"2018","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30536325","citation_count":16,"is_preprint":false},{"pmid":"35520131","id":"PMC_35520131","title":"Discovery of Cobimetinib as a novel A-FABP inhibitor using machine learning and molecular docking-based virtual screening.","date":"2022","source":"RSC advances","url":"https://pubmed.ncbi.nlm.nih.gov/35520131","citation_count":16,"is_preprint":false},{"pmid":"37833736","id":"PMC_37833736","title":"Prospective and Mendelian randomization analyses on the association of circulating fatty acid binding protein 4 (FABP-4) and risk of colorectal cancer.","date":"2023","source":"BMC medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37833736","citation_count":16,"is_preprint":false},{"pmid":"30521939","id":"PMC_30521939","title":"Extracellular FABP4 uptake by endothelial cells is dependent on cytokeratin 1 expression.","date":"2018","source":"Biochimica et biophysica acta. Molecular and cell biology of lipids","url":"https://pubmed.ncbi.nlm.nih.gov/30521939","citation_count":16,"is_preprint":false},{"pmid":"39212041","id":"PMC_39212041","title":"FABP4 Enhances Lipidic and Fibrotic Cardiac Structural and Ca2+ Dynamic Changes.","date":"2024","source":"Circulation. Arrhythmia and electrophysiology","url":"https://pubmed.ncbi.nlm.nih.gov/39212041","citation_count":15,"is_preprint":false},{"pmid":"39225895","id":"PMC_39225895","title":"Inhibition of the RXRA-PPARα-FABP4 signaling pathway alleviates vascular cellular aging by an SGLT2 inhibitor in an atherosclerotic mice model.","date":"2024","source":"Science China. Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/39225895","citation_count":15,"is_preprint":false},{"pmid":"33901630","id":"PMC_33901630","title":"PXR-mediated expression of FABP4 promotes valproate-induced lipid accumulation in HepG2 cells.","date":"2021","source":"Toxicology letters","url":"https://pubmed.ncbi.nlm.nih.gov/33901630","citation_count":15,"is_preprint":false},{"pmid":"35603953","id":"PMC_35603953","title":"SIRT5 promotes non-small cell lung cancer progression by reducing FABP4 acetylation level.","date":"2022","source":"Neoplasma","url":"https://pubmed.ncbi.nlm.nih.gov/35603953","citation_count":15,"is_preprint":false},{"pmid":"40360512","id":"PMC_40360512","title":"FABP4 inhibition suppresses bone resorption and protects against postmenopausal osteoporosis in ovariectomized mice.","date":"2025","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/40360512","citation_count":14,"is_preprint":false},{"pmid":"31651119","id":"PMC_31651119","title":"FABP4 levels in hypothyroidism and its relationship with subclinical atherosclerosis.","date":"2019","source":"Turkish journal of medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31651119","citation_count":14,"is_preprint":false},{"pmid":"38095503","id":"PMC_38095503","title":"Fatty acid binding protein 4 (FABP4) induces chondrocyte degeneration via activation of the NF-κb signaling pathway.","date":"2024","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/38095503","citation_count":14,"is_preprint":false},{"pmid":"39198543","id":"PMC_39198543","title":"Altered lipid metabolism promoting cardiac fibrosis is mediated by CD34+ cell-derived FABP4+ fibroblasts.","date":"2024","source":"Experimental & molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39198543","citation_count":13,"is_preprint":false},{"pmid":"39007036","id":"PMC_39007036","title":"Upregulation of FABP4 induced inflammation in the pathogenesis of chronic tendinopathy.","date":"2024","source":"Journal of orthopaedic translation","url":"https://pubmed.ncbi.nlm.nih.gov/39007036","citation_count":13,"is_preprint":false},{"pmid":"33666565","id":"PMC_33666565","title":"Oleanolic acid derivative HA-20 inhibits adipogenesis in a manner involving PPARγ-FABP4/aP2 pathway.","date":"2021","source":"Journal of molecular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/33666565","citation_count":13,"is_preprint":false},{"pmid":"36264920","id":"PMC_36264920","title":"Comprehensive analysis of the immune implication of FABP4 in colon adenocarcinoma.","date":"2022","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/36264920","citation_count":13,"is_preprint":false},{"pmid":"24491219","id":"PMC_24491219","title":"Lipocalin-2, A-FABP and inflammatory markers in relation to flow-mediated vasodilatation in patients with essential hypertension.","date":"2014","source":"Clinical and experimental hypertension (New York, N.Y. : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/24491219","citation_count":13,"is_preprint":false},{"pmid":"23091808","id":"PMC_23091808","title":"Enhanced A-FABP expression in visceral fat: potential contributor to the progression of NASH.","date":"2012","source":"Clinical and molecular hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/23091808","citation_count":13,"is_preprint":false},{"pmid":"24024500","id":"PMC_24024500","title":"Small molecule inhibitors of human adipocyte fatty acid binding protein (FABP4).","date":"2014","source":"Medicinal chemistry (Shariqah (United Arab Emirates))","url":"https://pubmed.ncbi.nlm.nih.gov/24024500","citation_count":12,"is_preprint":false},{"pmid":"24293757","id":"PMC_24293757","title":"Circulating FABP4 and FABP5 levels are differently linked to OSA severity and treatment.","date":"2013","source":"Sleep","url":"https://pubmed.ncbi.nlm.nih.gov/24293757","citation_count":12,"is_preprint":false},{"pmid":"38777142","id":"PMC_38777142","title":"Fatty acid binding to the human transport proteins FABP3, FABP4, and FABP5 from a Ligand's perspective.","date":"2024","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/38777142","citation_count":12,"is_preprint":false},{"pmid":"40090836","id":"PMC_40090836","title":"Targeting FABP4 to Inhibit AGEs-RAGE/NF-κB Signalling Effectively Ameliorates Nucleus Pulposus Dysfunction and Angiogenesis in Obesity-Related Intervertebral Disc Degeneration.","date":"2025","source":"Cell proliferation","url":"https://pubmed.ncbi.nlm.nih.gov/40090836","citation_count":12,"is_preprint":false},{"pmid":"39243502","id":"PMC_39243502","title":"FABP4 facilitates epithelial-mesenchymal transition via elevating CD36 expression in glioma cells.","date":"2024","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/39243502","citation_count":11,"is_preprint":false},{"pmid":"35647197","id":"PMC_35647197","title":"FABP4 and I-FABP Levels in Pregnant Women Are Associated with Body Mass Index but Not Gestational Diabetes.","date":"2022","source":"Journal of diabetes research","url":"https://pubmed.ncbi.nlm.nih.gov/35647197","citation_count":11,"is_preprint":false},{"pmid":"36311201","id":"PMC_36311201","title":"Inhibition of FABP4 attenuates cardiac fibrosis through inhibition of NLRP3 inflammasome activation.","date":"2022","source":"Iranian journal of basic medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36311201","citation_count":11,"is_preprint":false},{"pmid":"33151094","id":"PMC_33151094","title":"Elevated expression of FABP4 is associated with disease activity in rheumatoid arthritis patients.","date":"2020","source":"Biomarkers in medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33151094","citation_count":11,"is_preprint":false},{"pmid":"39823981","id":"PMC_39823981","title":"Targeting FABP4/UCP2 axis to overcome cetuximab resistance in obesity-driven CRC with drug-tolerant persister cells.","date":"2025","source":"Translational oncology","url":"https://pubmed.ncbi.nlm.nih.gov/39823981","citation_count":10,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":54477,"output_tokens":8671,"usd":0.146748,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":18608,"output_tokens":3871,"usd":0.094908,"stage2_stop_reason":"end_turn"},"total_usd":0.241656,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2021,\n      \"finding\": \"Hormonal FABP4 forms a functional hormone complex with adenosine kinase (ADK) and nucleoside diphosphate kinase (NDPK), designated 'Fabkin', to regulate extracellular ATP and ADP levels and thereby modulate beta-cell function; antibody-mediated targeting of this complex improved metabolic outcomes and preserved beta-cell integrity in mouse models of both type 1 and type 2 diabetes.\",\n      \"method\": \"Complex identification, in vivo mouse models (T1D and T2D), antibody-mediated targeting, measurement of extracellular ATP/ADP levels\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — complex reconstitution with functional readout, multiple disease models, antibody intervention, published in Nature\",\n      \"pmids\": [\"34880500\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"FABP4 triggers ubiquitination and subsequent proteasomal degradation of PPARγ in adipocytes and macrophages, thereby downregulating adipogenesis; FABP4-null preadipocytes exhibit markedly enhanced adipogenesis that is reversed by FABP4 complementation.\",\n      \"method\": \"Ubiquitination assay, proteasome inhibition, FABP4-null mouse preadipocytes and macrophages, complementation rescue experiment\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal genetic rescue, ubiquitination assay, and multiple cell-type validation in one study\",\n      \"pmids\": [\"24319114\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"FABP4 (A-FABP) promotes adaptive thermogenesis by inducing type-II iodothyronine deiodinase (DIO2) expression in brown adipocytes via inhibition of liver X receptor α (LXRα), leading to conversion of inactive T4 to active T3; A-FABP knockout mice have reduced thermogenesis reversible by recombinant A-FABP infusion.\",\n      \"method\": \"A-FABP knockout mice, cold stress and high-fat diet challenges, recombinant protein infusion rescue, gene expression analysis, LXRα inhibition assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — KO with specific phenotype, recombinant protein rescue, mechanistic pathway (LXRα inhibition → DIO2 induction) validated in multiple conditions\",\n      \"pmids\": [\"28128199\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"FABP4 secretion from adipocytes occurs via an unconventional pathway involving enclosure within endosomes and secretory lysosomes, independent of the ER-Golgi pathway, GRASP proteins, autophagy, and multivesicular bodies; chloroquine treatment inhibits plasma FABP4 elevation in mice.\",\n      \"method\": \"Subcellular fractionation, membrane-bounded compartment tracing, pharmacological inhibition (chloroquine) in mice, exclusion of alternative secretory routes\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods to define secretory pathway, in vivo validation with chloroquine, published in a top cell biology journal\",\n      \"pmids\": [\"29212659\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Endothelial cells are the major source of baseline circulating (hormonal) FABP4, contributing ~87% of basal plasma FABP4; adipocytes are the main source of the lipolysis-stimulated rise in plasma FABP4 (~62% of induction); myeloid cells do not contribute detectably to circulating FABP4. Endothelial-derived FABP4 is required for the insulin secretion response to lipolysis.\",\n      \"method\": \"Cell-type-specific Fabp4 knockout mice (adipocyte, endothelial, myeloid, total), plasma FABP4 measurement, lipolysis stimulation, insulin secretion assay\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — four cell-type-specific KO lines with rigorous in vivo quantification of plasma FABP4 and functional insulin secretion readout\",\n      \"pmids\": [\"37279064\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"PAK4 directly phosphorylates FABP4 at T126 and HSL at S565, impairing the FABP4–HSL interaction and inhibiting lipolysis; adipose-specific PAK4 overexpression attenuates lipolysis and exacerbates obesity, whereas PAK4 knockout or inhibition enhances lipolysis and ameliorates diet-induced obesity and insulin resistance. PKA targets PAK4 for degradation, placing PAK4 as a counter-regulatory node in the cAMP-PKA lipolysis pathway.\",\n      \"method\": \"In vitro kinase assay with phosphosite identification, adipose-specific PAK4 overexpression and KO mice, co-IP of FABP4–HSL, high-fat diet metabolic phenotyping, PAK4 inhibitor treatment\",\n      \"journal\": \"Nature metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct kinase assay with mutagenesis-level phosphosite identification, reciprocal Co-IP, multiple in vivo genetic models\",\n      \"pmids\": [\"38216738\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Ablation of FABP4/aP2 in macrophages upregulates UCP2, reduces mitochondrial protein oxidation and the mitochondrial unfolded-protein response, and attenuates NLRP3 inflammasome activation and IL-1β secretion; these effects are partially reversed by UCP2 silencing in FABP4-null macrophages, establishing a FABP4→UCP2→redox→NLRP3 pathway.\",\n      \"method\": \"FABP4-null macrophages, UCP2 siRNA rescue, ROS/protein oxidation assays, NLRP3 inflammasome activation (caspase-1 cleavage, IL-1β secretion), chemical FABP4 inhibitor\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO with genetic rescue (siRNA), multiple orthogonal mechanistic readouts, chemical inhibitor confirmation\",\n      \"pmids\": [\"27795298\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Macrophage-derived FABP4 is required for CXCL1 production by alveolar macrophages and subsequent neutrophil recruitment in Pseudomonas aeruginosa pneumonia; bone marrow chimera experiments confirmed macrophages as the protective FABP4 source, and recombinant CXCL1 delivery rescued FABP4-null mice from increased mortality.\",\n      \"method\": \"FABP4-knockout mice, bone marrow chimera reconstitution, intratracheal P. aeruginosa challenge, recombinant CXCL1 rescue, CXCL1 ELISA from alveolar macrophages\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal chimera experiment, in vivo rescue with recombinant protein, cell-type-specific attribution of CXCL1 production\",\n      \"pmids\": [\"30462529\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"SIRT5 physically interacts with FABP4 (Co-IP) and promotes FABP4 deacetylation, reducing FABP4 expression and thereby promoting non-small cell lung cancer progression; silencing SIRT5 increases FABP4 acetylation and expression, reducing cancer cell malignancy.\",\n      \"method\": \"Co-immunoprecipitation, western blot for acetylation, shRNA knockdown of SIRT5 and FABP4 in NSCLC cells, in vivo xenograft\",\n      \"journal\": \"Neoplasma\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — Co-IP interaction and functional rescue, single lab, limited mechanistic depth on deacetylase specificity\",\n      \"pmids\": [\"35603953\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"FABP4 interacts with cytokeratin 1 (CK1) on the endothelial cell surface (demonstrated by surface plasmon resonance); CK1-mediated FABP4 uptake regulates endothelial oxidative stress (NRF2) and inflammation (NF-κB/p65) responses, and CK1 knockdown blocks eFABP4 pro-inflammatory and pro-oxidative effects.\",\n      \"method\": \"Surface plasmon resonance (direct binding), siRNA knockdown of CK1 in HUVECs, western blotting for NRF2 and p65 nuclear translocation, palmitate co-treatment\",\n      \"journal\": \"Biochimica et biophysica acta. Molecular and cell biology of lipids\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — SPR direct binding with domain mapping, functional KD validation, single lab\",\n      \"pmids\": [\"30521939\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CD36 directly interacts with FABP4 to regulate fatty acid import, transport, and metabolism in breast cancer cells co-cultured with adipocytes; CD36 activates STAT3 signalling with a feedforward loop (STAT3 binds CD36 promoter), and combined CD36/FABP4 inhibition induces apoptosis.\",\n      \"method\": \"Co-culture experiments, genetic ablation of CD36, Co-IP of CD36–FABP4 interaction, ChIP/reporter for STAT3-CD36 promoter binding, apoptosis assays\",\n      \"journal\": \"NPJ breast cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — direct Co-IP interaction, functional genetic ablation, single lab\",\n      \"pmids\": [\"34561446\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"FABP4 in tumor-associated macrophages directly binds to ATP synthase β subunit (ATPB) and promotes its ubiquitination, leading to decreased intracellular ATP and deactivation of the NF-κB/RelA–IL-1α pathway, reprogramming macrophages to an anti-inflammatory phenotype that promotes neuroblastoma progression.\",\n      \"method\": \"Co-IP of FABP4–ATPB, ubiquitination assay, ATP measurement, NF-κB pathway analysis, IL-1α blocking antibody rescue, in vitro and in vivo tumor progression assays\",\n      \"journal\": \"Clinical and translational medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — Co-IP and ubiquitination assay with functional rescue, single lab\",\n      \"pmids\": [\"33931964\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"FABP4 activates the JAK2/STAT2 signaling pathway in homocysteine-induced macrophage inflammation via Rap1a-mediated Tyr416 phosphorylation and membrane translocation of c-Src; SOCS1 provides negative feedback inhibition of this pathway and reduces Rap1a expression.\",\n      \"method\": \"Western blot for JAK2/STAT2 and c-Src phosphorylation, Rap1a manipulation, pharmacological inhibition in ApoE-/- mice, pathway inhibitor studies\",\n      \"journal\": \"Laboratory investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — defined signaling pathway with multiple nodes validated, single lab, in vivo and in vitro\",\n      \"pmids\": [\"34725437\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"FABP4 activates the AMPK/JAK/STAT axis in a novel FABP4+C1q+ macrophage subtype, promoting fatty acid synthesis, anti-apoptosis, and phagocytic ability; FABP4 and C1q synergistically regulate proinflammatory cytokine expression in these macrophages.\",\n      \"method\": \"Single-cell RNA sequencing, multiplex fluorescent immunohistochemistry, mechanistic pathway (AMPK/JAK/STAT) analysis, functional phagocytosis/apoptosis assays\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — scRNA-seq identifies subtype, mechanistic pathway stated from 'further mechanistic studies' with limited biochemical detail in abstract\",\n      \"pmids\": [\"39353883\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"FABP4 in liver sinusoidal endothelial cells (LSECs) promotes CXCL10 expression via NF-κB/p65 signaling, driving CXCR3+ macrophage recruitment and M1 macrophage polarization during NAFLD progression; FABP4 inhibition reduces CXCL10 and M1 polarization.\",\n      \"method\": \"FABP4 inhibition in HFD mice, flow cytometry for macrophage subtypes, co-culture of TMNK-1 cells with macrophages, NF-κB inhibitor, recombinant CXCL10 treatment\",\n      \"journal\": \"Biochimica et biophysica acta. Molecular basis of disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — pathway (NF-κB→CXCL10) validated with inhibitor and recombinant protein, in vivo and in vitro, single lab\",\n      \"pmids\": [\"37487374\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"FABP4 supports fatty acid-induced PPARγ activation in IL-4-polarized macrophages, leading to upregulation of lipoprotein lipase (LPL), VLDL-induced triglyceride accumulation (foam cell formation), and CCL2/IL-1β inflammatory mediator expression; FABP4 inhibition (chemical or siRNA) reduces all these effects.\",\n      \"method\": \"FABP4 siRNA knockdown, chemical inhibitors (BMS309403, HTS01037), PPARγ luciferase reporter assay, lipid accumulation assay in primary human macrophages\",\n      \"journal\": \"Atherosclerosis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — PPARγ reporter assay plus siRNA and chemical inhibitor in primary human macrophages, single lab\",\n      \"pmids\": [\"25897794\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Exogenous FABP4 activates p38 MAPK, which mediates both HSL (Ser-660) phosphorylation-dependent lipolysis and NF-κB-mediated inflammation in adipocytes; these effects are blocked by the p38 inhibitor SB203580 and FABP4 inhibitor I-9 in vitro and in vivo.\",\n      \"method\": \"Recombinant FABP4 treatment of 3T3-L1 cells and C57BL/6J mice, western blot for p38, HSL-pSer660, NF-κB, p38 and FABP4 inhibitor intervention\",\n      \"journal\": \"Endocrine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — signaling pathway validated with specific inhibitors in vitro and in vivo, single lab\",\n      \"pmids\": [\"31845180\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Microglial FABP4 deficiency prevents high-fat diet-induced cognitive decline in mice, associated with reduced hippocampal neuroinflammation (inflammatory cytokines and microgliosis) and increased microglial UCP2 expression, defining a microglial FABP4–UCP2 axis in diet-induced neuroinflammation.\",\n      \"method\": \"Microglial-specific FABP4 knockout (AKO) mice, HFD challenge, behavioral testing (T-maze, Barnes maze), hippocampal cytokine panel, UCP2 RT-PCR, IHC for microgliosis\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-type-specific KO with defined behavioral and molecular phenotype, multiple orthogonal readouts, single lab\",\n      \"pmids\": [\"35457171\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"FABP4 expression in eosinophils is induced by TNF-α, IL-4, and IL-13; FABP4-deficient eosinophils show decreased spreading, adhesion (reduced β2-integrin), migration, F-actin polymerization, calcium flux, and ERK1/2 phosphorylation in response to eotaxin-1; in vivo, FABP4-null mice exhibit attenuated eosinophilia and airway inflammation in a cockroach antigen model.\",\n      \"method\": \"FABP4-knockout mice, allergen challenge model, eosinophil adhesion and migration assays, calcium flux measurement, ERK1/2 western blot, F-actin polymerization assay\",\n      \"journal\": \"American journal of physiology. Lung cellular and molecular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal in vitro assays plus in vivo KO model, single lab\",\n      \"pmids\": [\"29696987\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"FABP4 directly activates NF-κB signaling in chondrocytes (validated in ATDC5 cells and FABP4-KO vs WT mice), leading to upregulation of catabolic markers; dual FABP4 and NF-κB inhibition alleviates OA in high-fat diet mice, whereas FABP4 had no significant effect on JNK signaling in this context.\",\n      \"method\": \"FABP4-KO mice, NF-κB-specific inhibitor (QNZ) and siRNA, FABP4 inhibitor (BMS309403), ATDC5 chondrocyte culture with recombinant FABP4, HFD OA model\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — genetic KO, specific inhibitors and siRNA, in vitro direct stimulation, single lab\",\n      \"pmids\": [\"38095503\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"FABP4 inhibition (BMS309403) suppresses osteoclast differentiation by modulating calcium signaling and inhibiting the Ca2+-Calcineurin-NFATc1 pathway, without affecting osteoblast differentiation, and increases bone mineral density in ovariectomized mice.\",\n      \"method\": \"Osteoclast/osteoblast differentiation assays, Ca2+ signaling and NFATc1 pathway analysis, ovariectomized mouse model with BMS309403 treatment, bone mineral density measurement\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — defined pathway (Ca2+-Calcineurin-NFATc1) with pharmacological inhibition and in vivo disease model, single lab\",\n      \"pmids\": [\"40360512\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"FABP4 activates the FABP4/CEBPα pathway in macrophages in response to unsaturated fatty acids (particularly linoleic acid), leading to triglyceride synthesis and lipid droplet formation; FABP4 also enhances lipolysis and FA utilization by breast cancer cells, promoting metastasis in vitro and in vivo; FABP4 deficiency in macrophages significantly reduces linoleic acid-induced lipid metabolism.\",\n      \"method\": \"Murine macrophage lipid droplet formation assays, FABP4-deficient macrophages, CEBPα pathway analysis, co-culture with breast cancer cell lines, migration assays, in vivo metastasis model\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — genetic KO with multiple orthogonal assays (lipid metabolism, signaling, migration, in vivo), single lab\",\n      \"pmids\": [\"39513934\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"FABP4 in macrophages activates the NLRP3/IL-1β axis by facilitating transfer of saturated fatty acids to induce caspase-1/GSDMD-dependent pyroptosis, which then promotes EMT signaling in pancreatic cancer cells to drive metastasis.\",\n      \"method\": \"In vivo and in vitro experiments with FABP4-overexpressing macrophages, caspase-1/GSDMD pathway analysis, NLRP3 inhibition, co-culture of macrophages with PC cells, EMT marker assessment\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — defined pathway with multiple nodes validated in vitro and in vivo, single lab\",\n      \"pmids\": [\"37741433\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"FABP4 facilitates EMT in glioblastoma cells by upregulating CD36 expression, which promotes EMT via non-canonical TGFβ pathways; FABP4 overexpression increases filopodia formation and invasion, and loss-of-function reduces these effects in vitro and in an intracranial model.\",\n      \"method\": \"Gain- and loss-of-function experiments, DEG and GSEA analysis, CD36 expression assays, non-canonical TGFβ pathway western blot, intracranial glioma mouse model\",\n      \"journal\": \"Neoplasia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — mechanistic pathway through CD36/TGFβ with in vitro and in vivo validation, single lab\",\n      \"pmids\": [\"39243502\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Nitro-fatty acids (NO2-FA) bind directly to FABP4 (demonstrated in vitro and in silico), and FABP4 facilitates NO2-FA-induced PPARγ, Keap1/Nrf2, and HSF1 signaling in monocytes; FABP4 inhibition attenuates these downstream signaling actions, establishing a FABP4-PPARγ positive amplification loop for NO2-FA signaling.\",\n      \"method\": \"In vitro fatty acid binding assay, molecular docking (in silico), FABP4 inhibitor treatment, PPARγ reporter gene assays in primary human monocytes/macrophages\",\n      \"journal\": \"Redox biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — direct binding demonstrated by in vitro and in silico approaches, functional inhibitor validation, single lab\",\n      \"pmids\": [\"31926616\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"FABP4 promotes survival and alarming function of islet-resident memory T cells (TRM) by promoting fatty acid utilization and CXCL10 secretion; genetic deletion of FABP4 in NOD mice reduced cytotoxic T cell recruitment, delayed T1D incidence, and suppressed CXCL10 production.\",\n      \"method\": \"NOD mouse FABP4 genetic deletion, CD69 neutralizing antibody depletion of TRM cells, flow cytometry for T cell populations, CXCL10 measurement, diabetes incidence tracking\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO with disease incidence readout and mechanistic CXCL10 link, parallel TRM depletion producing similar phenotype, single lab\",\n      \"pmids\": [\"38884133\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"FABP4 controls fat mass homeostasis (adipocyte size and number) through a negative feedback loop: fatty acid-mediated FAT/CD36-PPARγ signaling induces FABP4 expression, and accumulated intracellular FABP4 in turn inhibits CD36 signaling in both adipocytes and progenitors.\",\n      \"method\": \"Real-time proliferation/differentiation/lipolysis assays in 3T3-L1, 3T3-MBX, and human adipose stem cells; co-culture; FABP4 uptake and CD36 signaling measurements\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — cell-based assays with mechanistic proposal, single lab, limited biochemical depth in abstract\",\n      \"pmids\": [\"36674544\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"FABP4 expressed in Paneth cells is regulated by gut Lactobacillus via TRAF2/TRAF6 ubiquitination-mediated NF-κB signaling; germ-free mice have reduced intestinal FABP4, restored by fecal transplantation or specific Lactobacillus colonization.\",\n      \"method\": \"Germ-free mice, fecal transplantation, Lactobacillus colonization, TRAF2/TRAF6 ubiquitination and NF-κB pathway analysis, Paneth cell-specific FABP4 expression assessment\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — pathway identified but mechanistic link between TRAF2/6 NF-κB and FABP4 induction in Paneth cells has limited biochemical detail in abstract, single lab\",\n      \"pmids\": [\"26687459\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Fatty acid binding to FABP4 occurs in two distinct states ('intermediately' and 'strongly' bound) as revealed by CW EPR spectroscopy using spin-labeled stearic acid; binding proportions are strongly temperature- and concentration-dependent with the more dynamic 'intermediately bound' state dominating at body temperature.\",\n      \"method\": \"Microscale thermophoresis (MST), continuous-wave electron paramagnetic resonance (CW EPR) spectroscopy with spin-probe ligands, dynamic light scattering, bioinformatic analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — biophysical characterization of ligand binding mechanism with two orthogonal methods, single lab, no mutagenesis or cellular functional validation\",\n      \"pmids\": [\"38777142\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Kindlin-2 stabilizes fatty acid synthase (FAS) and promotes PPARγ activation and downstream FABP4 expression in adipocytes; increased FABP4 inhibits insulin expression and decreases bone mass; Kindlin-2 deletion reduces FABP4 and increases bone mass, reversible by PPARγ activation (rosiglitazone), establishing a Kindlin-2/FAS/PPARγ/FABP4/insulin axis.\",\n      \"method\": \"Adipocyte-specific Kindlin-2 KO mice, AAV-targeted knockdown, FAS inhibitor (C75), rosiglitazone rescue, FAS protein stability assay, PPARγ activation assay, bone density measurement\",\n      \"journal\": \"Acta pharmaceutica Sinica. B\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO with pharmacological rescue defining epistatic pathway, multiple in vivo and in vitro validations, single lab\",\n      \"pmids\": [\"37969743\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"PXR mediates FABP4 expression in response to valproate in HepG2 cells; PXR knockdown reduces both FABP4 induction and lipid accumulation, while PXR overexpression enhances both; exogenous FABP4 overexpression independently increases triglyceride levels.\",\n      \"method\": \"PXR siRNA knockdown, PXR overexpression, FABP4 overexpression, triglyceride measurement, lipid accumulation assay in HepG2 cells\",\n      \"journal\": \"Toxicology letters\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — cell-based assays with genetic manipulations, single lab, indirect pathway inference\",\n      \"pmids\": [\"33901630\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"mTORC1 activity (controlled by TSC1 deletion or Rheb1 disruption in myeloid cells) regulates FABP4 expression in macrophages; mTORC1 activation increases FABP4 secretion from M1-polarized macrophages, promoting synovitis, angiogenesis, and cartilage degradation in RA; anagliptin (DPP4 inhibitor) and BMS309403 (FABP4 inhibitor) reduce FABP4 in synovial macrophages and alleviate RA.\",\n      \"method\": \"Myeloid-specific TSC1-deletion and Rheb1-disruption mice, BMS309403 and anagliptin treatment, in vivo RA mouse model, synovitis/angiogenesis/cartilage assays\",\n      \"journal\": \"Bone research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — myeloid-specific genetic models defining mTORC1→FABP4 axis, pharmacological validation, in vivo disease readouts, single lab\",\n      \"pmids\": [\"35729106\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"FABP4 induces fibrosis, lipid accumulation, and altered glucose metabolism in epicardial stroma and atrial fibroblasts, and modifies lipid content and calcium dynamics in atrial cardiomyocytes, without affecting INa; these effects were demonstrated by direct FABP4 protein treatment of primary cell cultures.\",\n      \"method\": \"Primary epicardial/subcutaneous stroma and atrial fibroblast cultures, iPSC-derived and adult mouse atrial cardiomyocytes, FABP4 (100 ng/mL) treatment, proteomics, Raman microspectroscopy, calcium imaging, patch clamp\",\n      \"journal\": \"Circulation. Arrhythmia and electrophysiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple primary cell types, orthogonal methods including electrophysiology and proteomics, direct protein treatment, single lab\",\n      \"pmids\": [\"39212041\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"FABP4 is an intracellular lipid chaperone and secreted hormone (released from adipocytes during lipolysis and constitutively from endothelial cells) that forms a functional hormone complex (Fabkin) with ADK and NDPK to regulate extracellular nucleotide levels and beta-cell function; intracellularly, it promotes proteasomal degradation of PPARγ to suppress adipogenesis, controls macrophage redox signaling and NLRP3 inflammasome activation via UCP2, is phosphorylated by PAK4 at T126 to impair its interaction with HSL and inhibit lipolysis, and is deacetylated by SIRT5; extracellularly, it signals through cytokeratin 1 on endothelial cells to activate NF-κB and oxidative stress pathways, and in brown adipocytes promotes thermogenesis by inhibiting LXRα to induce DIO2-mediated T4-to-T3 conversion.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"FABP4 is a fatty acid-binding protein that functions both as an intracellular lipid chaperone and as a secreted hormone coordinating lipid metabolism, inflammation, and systemic glucose homeostasis [#0, #4]. As a circulating hormone, FABP4 is released from adipocytes upon lipolytic stimulation and constitutively from endothelial cells, which supply the majority of basal plasma FABP4 and are required for the lipolysis-driven insulin secretion response [#4]; its secretion proceeds through an unconventional ER-Golgi-independent route involving endosomes and secretory lysosomes [#3]. Once extracellular, FABP4 assembles with adenosine kinase and nucleoside diphosphate kinase into the 'Fabkin' complex that regulates extracellular ATP/ADP levels and modulates beta-cell function, and antibody targeting of this complex improves metabolic outcomes in diabetes models [#0]; it also engages cytokeratin 1 on the endothelial surface to drive NRF2 oxidative-stress and NF-\\u03baB inflammatory signaling [#9]. Intracellularly, FABP4 binds fatty acids in distinct dynamic states [#28] and shapes nuclear-receptor signaling: it triggers ubiquitin-proteasomal degradation of PPAR\\u03b3 to restrain adipogenesis [#1], yet supports fatty acid-induced PPAR\\u03b3 activation and lipid signaling in polarized macrophages [#15, #24]. Its lipolytic role is gated by PAK4, which phosphorylates FABP4 at T126 to impair the FABP4\\u2013HSL interaction and suppress lipolysis [#5]. In brown adipocytes FABP4 promotes adaptive thermogenesis by inhibiting LXR\\u03b1 to induce DIO2-mediated T4-to-T3 conversion [#2], and in macrophages it controls a UCP2-dependent redox circuit that governs NLRP3 inflammasome activation and IL-1\\u03b2 output [#6]. Across diverse immune and stromal contexts FABP4 acts as a pro-inflammatory node, driving NF-\\u03baB-dependent chemokine production and macrophage recruitment in tissue and tumor microenvironments [#14, #11, #21].\",\n  \"teleology\": [\n    {\n      \"year\": 2013,\n      \"claim\": \"Established that beyond lipid binding FABP4 actively regulates the master adipogenic transcription factor PPAR\\u03b3, explaining how it restrains fat-cell formation.\",\n      \"evidence\": \"Ubiquitination and proteasome-inhibition assays with FABP4-null preadipocyte/macrophage complementation rescue\",\n      \"pmids\": [\"24319114\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not define the E3 ligase or direct biochemical mechanism of PPAR\\u03b3 ubiquitination\", \"Reconciliation with FABP4 supporting PPAR\\u03b3 activation in macrophages unresolved\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Showed FABP4 drives adaptive thermogenesis through an LXR\\u03b1\\u2192DIO2 axis, linking the chaperone to thyroid hormone activation in brown fat.\",\n      \"evidence\": \"A-FABP knockout mice with cold/HFD challenge and recombinant protein rescue, LXR\\u03b1 inhibition assays\",\n      \"pmids\": [\"28128199\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which FABP4 inhibits LXR\\u03b1 not defined\", \"Direct vs indirect effect on DIO2 transcription unclear\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Defined the unconventional secretory route for FABP4, resolving how a cytosolic protein reaches the circulation.\",\n      \"evidence\": \"Subcellular fractionation, exclusion of ER-Golgi/GRASP/autophagy/MVB routes, chloroquine inhibition in vivo\",\n      \"pmids\": [\"29212659\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular machinery sorting FABP4 into endosomes/secretory lysosomes unknown\", \"Signal triggering release not identified\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Connected FABP4 to a UCP2-dependent redox circuit controlling NLRP3 inflammasome activity, a mechanism for its pro-inflammatory action in macrophages.\",\n      \"evidence\": \"FABP4-null macrophages with UCP2 siRNA rescue, ROS/protein-oxidation and caspase-1/IL-1\\u03b2 readouts, chemical inhibitor\",\n      \"pmids\": [\"27795298\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How FABP4 represses UCP2 mechanistically not established\", \"Link between lipid binding and mitochondrial redox not biochemically resolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identified FABP4 as a secreted hormone forming the Fabkin complex that regulates extracellular nucleotides and beta-cell function, a paradigm-shifting extracellular role.\",\n      \"evidence\": \"Complex identification, T1D/T2D mouse models, antibody-mediated targeting, extracellular ATP/ADP measurement\",\n      \"pmids\": [\"34880500\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of the Fabkin assembly not resolved\", \"Receptor/sensing mechanism on beta-cells unclear\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Demonstrated a direct extracellular receptor for FABP4 (cytokeratin 1) on endothelial cells, defining how circulating FABP4 transmits oxidative/inflammatory signals.\",\n      \"evidence\": \"Surface plasmon resonance binding, CK1 siRNA knockdown in HUVECs, NRF2/p65 readouts\",\n      \"pmids\": [\"30521939\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab, no in vivo CK1 genetic validation\", \"Downstream signal transduction from CK1 not defined\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Quantified the cellular origins of circulating FABP4, showing endothelium supplies basal hormone and adipocytes the lipolytic surge, refining the source of the metabolic hormone.\",\n      \"evidence\": \"Four cell-type-specific Fabp4 knockout lines, plasma FABP4 quantification, lipolysis and insulin secretion assays\",\n      \"pmids\": [\"37279064\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of constitutive endothelial secretion not defined\", \"How endothelial FABP4 couples to islet insulin secretion unresolved\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Placed FABP4 under kinase control by PAK4, identifying a phosphosite that gates the FABP4\\u2013HSL interaction and lipolysis within the cAMP-PKA axis.\",\n      \"evidence\": \"In vitro kinase assay with phosphosite mapping (T126), adipose-specific PAK4 OE/KO mice, FABP4\\u2013HSL co-IP\",\n      \"pmids\": [\"38216738\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural effect of T126 phosphorylation on FABP4 not resolved\", \"Whether phospho-FABP4 alters lipid binding unknown\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Characterized the biophysics of FABP4 ligand binding, revealing temperature-dependent intermediate and strongly bound fatty acid states.\",\n      \"evidence\": \"Microscale thermophoresis and CW EPR with spin-labeled stearic acid\",\n      \"pmids\": [\"38777142\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No mutagenesis linking binding states to function\", \"Cellular relevance of the two states untested\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Extended FABP4's pro-inflammatory function across tissues, showing NF-\\u03baB-driven chemokine programs in endothelium, macrophages, T cells, and stroma promote recruitment and disease in metabolic, autoimmune, and tumor settings.\",\n      \"evidence\": \"Cell-type-specific KO and inhibitor studies across NAFLD, NOD diabetes, cancer co-culture and metastasis models with CXCL10/CXCL1/IL-1 readouts\",\n      \"pmids\": [\"37487374\", \"38884133\", \"30462529\", \"37741433\", \"39513934\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether these effects depend on intracellular lipid chaperoning or extracellular signaling not always distinguished\", \"Most contexts validated in single labs\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How a single fatty acid-binding protein reconciles opposing roles (PPAR\\u03b3 degradation vs activation; intracellular chaperone vs extracellular hormone) and the structural/receptor basis of its extracellular signaling remain open.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unifying structural model linking ligand state, phosphorylation, and partner choice\", \"Extracellular receptor repertoire beyond CK1 unresolved\", \"Mechanism switching FABP4 between pro- and anti-adipogenic outputs unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [28, 24]},\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 9]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [1, 2, 5]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [3, 5]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 4]},\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [3]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [3]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [1, 2, 26]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [6, 14, 7]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 9, 5]},\n      {\"term_id\": \"R-HSA-9609507\", \"supporting_discovery_ids\": [3]}\n    ],\n    \"complexes\": [\"Fabkin (FABP4-ADK-NDPK)\"],\n    \"partners\": [\"ADK\", \"NDPK\", \"HSL\", \"PAK4\", \"PPARG\", \"KRT1\", \"CD36\", \"SIRT5\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"tie","faith_supported":7,"faith_total":7,"faith_pct":100.0}}